Ch Doehn

Summary

Country: Germany

Publications

  1. doi Outcome analysis of fornix ruptures in 162 consecutive patients
    Christian Doehn
    Department of Urology, University of Lubeck Medical School, Lubeck, Germany
    J Endourol 24:1869-73. 2010
  2. ncbi Vaccination immunotherapy--an update
    C Doehn
    Department of Urology, University of Lubeck Medical School, Lubeck, Germany
    Scand J Surg 93:163-9. 2004
  3. ncbi Cytokine and vaccine therapy of kidney cancer
    Christian Doehn
    Department of Urology, University of Lubeck Medical School, Ratzeburger Allee 160, 23538 Lubeck, Germany
    Expert Rev Anticancer Ther 4:1097-111. 2004
  4. ncbi Drug evaluation: Degarelix--a potential new therapy for prostate cancer
    Christian Doehn
    Department of Urology, University of Lubeck Medical School, Ratzeburger Allee 160, 23538 Lubeck, Germany
    IDrugs 9:565-72. 2006
  5. ncbi [Vaccine therapy of prostate cancer]
    C Doehn
    Klinik und Poliklinik fur Urologie, Universitätsklinikum Schleswig Holstein UKSH, Campus Lubeck
    Aktuelle Urol 36:407-16. 2005
  6. ncbi Technology evaluation: Onyvax-P, Onyvax
    Christian Doehn
    University of Lubeck Medical School, Department of Urology, Lubeck, Germany
    Curr Opin Mol Ther 7:511-9. 2005
  7. ncbi Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine
    Christian Doehn
    University of Lubeck Medical School, Department of Urology, Ratzeburger Allee 160, 23538 Lubeck, Germany
    Curr Opin Mol Ther 9:183-9. 2007
  8. ncbi [Is there an indication for neoadjuvant or adjuvant systemic therapy in renal cell cancer?]
    C Doehn
    Klinik und Poliklinik fur Urologie, Universitätsklinikum Schleswig Holstein UK S H, Campus Lubeck, Ratzeburger Allee 160, 23538 Lubeck
    Urologe A 46:1371-2, 1374, 1376-8. 2007
  9. doi [New drugs for metastatic kidney cancer]
    C Doehn
    Klinik und Poliklinik fur Urologie, Universitatsklinikum Schleswig Holstein, Campus Lubeck, Lubeck, Deutschland
    Aktuelle Urol 39:41-52. 2008
  10. doi Results of secondary ureteral implantation after kidney transplantation
    Christian Doehn
    Department of Urology, University of Lubeck Medical School, Ratzeburger Allee 160, 23538 Lubeck, Germany
    Int Urol Nephrol 43:669-74. 2011

Detail Information

Publications42

  1. doi Outcome analysis of fornix ruptures in 162 consecutive patients
    Christian Doehn
    Department of Urology, University of Lubeck Medical School, Lubeck, Germany
    J Endourol 24:1869-73. 2010
    ..Fornix rupture is a potential urologic emergency. In most cases, ureteral stones represent the underlying cause. Management of a fornix rupture is not standardized...
  2. ncbi Vaccination immunotherapy--an update
    C Doehn
    Department of Urology, University of Lubeck Medical School, Lubeck, Germany
    Scand J Surg 93:163-9. 2004
    ..Ongoing efforts focus on development of more powerful vaccines. This review summarizes vaccination approaches for renal cell carcinomas published in the past 4 years...
  3. ncbi Cytokine and vaccine therapy of kidney cancer
    Christian Doehn
    Department of Urology, University of Lubeck Medical School, Ratzeburger Allee 160, 23538 Lubeck, Germany
    Expert Rev Anticancer Ther 4:1097-111. 2004
    ..Vaccine therapy of metastatic kidney cancer has been investigated only in Phase I and II studies with limited clinical benefit. Based on the current literature there is a clear need for new approaches in metastatic kidney cancer...
  4. ncbi Drug evaluation: Degarelix--a potential new therapy for prostate cancer
    Christian Doehn
    Department of Urology, University of Lubeck Medical School, Ratzeburger Allee 160, 23538 Lubeck, Germany
    IDrugs 9:565-72. 2006
    ..Ferring Research Ltd and licensee Astellas Pharma Inc are developing the gonadotropin-releasing hormone antagonist degarelix as a potential subcutaneous treatment for prostate cancer...
  5. ncbi [Vaccine therapy of prostate cancer]
    C Doehn
    Klinik und Poliklinik fur Urologie, Universitätsklinikum Schleswig Holstein UKSH, Campus Lubeck
    Aktuelle Urol 36:407-16. 2005
    ..Side effects of vaccination are generally mild. At present, there are trials are being planned or are already ongoing that combine vaccine with other treatment strategies or enroll patients with earlier disease stages...
  6. ncbi Technology evaluation: Onyvax-P, Onyvax
    Christian Doehn
    University of Lubeck Medical School, Department of Urology, Lubeck, Germany
    Curr Opin Mol Ther 7:511-9. 2005
    ..Onyvax is developing Onyvax-P, an allogeneic whole-cell vaccine, for the potential treatment of prostate cancer. The vaccine is currently undergoing phase II clinical trials...
  7. ncbi Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine
    Christian Doehn
    University of Lubeck Medical School, Department of Urology, Ratzeburger Allee 160, 23538 Lubeck, Germany
    Curr Opin Mol Ther 9:183-9. 2007
    ..1 and lymphocyte function-associated antigen-3), and a booster injection with a fowlpox virus expressing the same combination, for the potential treatment of prostate cancer. Phase II clinical trials are underway...
  8. ncbi [Is there an indication for neoadjuvant or adjuvant systemic therapy in renal cell cancer?]
    C Doehn
    Klinik und Poliklinik fur Urologie, Universitätsklinikum Schleswig Holstein UK S H, Campus Lubeck, Ratzeburger Allee 160, 23538 Lubeck
    Urologe A 46:1371-2, 1374, 1376-8. 2007
    ..New trials are testing tyrosine kidney inhibitors such as sunitinib and sorafenib...
  9. doi [New drugs for metastatic kidney cancer]
    C Doehn
    Klinik und Poliklinik fur Urologie, Universitatsklinikum Schleswig Holstein, Campus Lubeck, Lubeck, Deutschland
    Aktuelle Urol 39:41-52. 2008
    ..At present, the following scenarios have an impact on therapy decisions: different prognostic groups, first-line and second-line therapy, combination therapies and the impact of different histological subtypes...
  10. doi Results of secondary ureteral implantation after kidney transplantation
    Christian Doehn
    Department of Urology, University of Lubeck Medical School, Ratzeburger Allee 160, 23538 Lubeck, Germany
    Int Urol Nephrol 43:669-74. 2011
    ..We reviewed our experience with ureteral complications and secondary ureteral implantation after kidney transplantation...
  11. ncbi Prostate cancer vaccines: current status and future potential
    Christian Doehn
    Department of Urology, University of Lubeck Medical School, Lubeck, Germany
    BioDrugs 22:71-84. 2008
    ....
  12. doi Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma
    Christian Doehn
    Department of Urology, University of Lubeck Medical School, Lubeck, Germany
    Eur Urol 56:123-31. 2009
    ..This clinical trial focused on efficacy and did not investigate end-points relating to mode-of-action of the vaccine. In a murine model we investigated mode-of-action, efficacy, and safety of a homologous RENCA cell-based vaccine...
  13. doi Degarelix for prostate cancer
    Christian Doehn
    Department of Urology, University of Lubeck Medical School, Ratzeburger Allee 160, Lubeck, Germany
    Expert Opin Investig Drugs 18:851-60. 2009
    ..This review summarizes the preclinical and clinical data available for degarelix and describes its potential role in the market of prostate cancer therapeutics...
  14. pmc Degarelix and its therapeutic potential in the treatment of prostate cancer
    Christian Doehn
    Department of Urology, University of Lubeck Medical School, Lubeck, Germany
    Clin Interv Aging 4:215-23. 2009
    ..However, degarelix was recently approved by the US Food and Drug Administration for the treatment of advanced prostate cancer...
  15. doi [Causes and course of fornix rupture]
    C Doehn
    Klinik und Poliklinik fur Urologie, Universitätsklinikum Schleswig Holstein UK S H, Campus Lubeck
    Aktuelle Urol 41:119-21. 2010
    ..Fornix rupture is a urological emergency situation. In most cases ureteral stones represent the underlying cause. We present the largest series ever reported...
  16. doi Whose transplant function fails after ureteral revision following kidney transplantation?
    C Doehn
    Department of Urology, University of Lubeck Medical School, Lubeck, Germany
    Transplant Proc 42:1716-8. 2010
    ..In a retrospective analysis, we compared patients with versus without loss of transplant function after operative revision for a ureteral complication...
  17. ncbi [Immunotherapy of renal cell carcinoma: results from current phase-III-trials]
    C Doehn
    Klinik und Poliklinik fur Urologie, Universitatsklinikum Schleswig Holstein, Campus Lubeck
    Aktuelle Urol 35:121-9. 2004
    ..This review presents the results from current phase-III-trials investigating immunotherapy for renal carcinoma...
  18. ncbi Laparoscopic nephroureterectomy to exclude upper urinary tract malignancy associated with analgesic nephropathy
    C Doehn
    Department of Urology, Medical University of Lubeck, Germany
    J Endourol 15:809-14. 2001
    ..All patients were scheduled to be put on the waiting list for cadaveric renal transplantation...
  19. ncbi Technology evaluation: Abarelix, Praecis pharmaceuticals
    C Doehn
    Department of Urology, Medical University of Luebeck, Ratzeburger Allee 160, 23538 Luebeck, Germany
    Curr Opin Mol Ther 2:579-85. 2000
    ..In October 1999, Merrill Lynch predicted sales in 2003 of EUR 100 million [346209] and Lehman Brothers predicted sales of US$50 million in 2002 rising to a peak of US$150 million in 2010 [346267]...
  20. ncbi Technology evaluation: CV-787, Calydon Inc
    C Doehn
    Department of Urology, Medical University of Luebeck, Ratzeburger Allee 160, 23538 Luebeck, Germany
    Curr Opin Mol Ther 3:204-10. 2001
    ..The primary objectives of this trial are to determine the safety, tolerability, and PSA efficacy of CV-787 administered intravenously to patients with end-stage prostate cancer [384039]...
  21. ncbi [Surgical therapy of penis carcinoma]
    C Doehn
    Klinik und Poliklinik fur Urologie, Medizinische Universitat, Ratzeburger Allee 160, 23538 Lubeck
    Urologe A 40:303-7. 2001
    ..In cases of inguinal lymph node metastasis, removal of the iliac lymph nodes (one- or two-step procedure) is necessary...
  22. ncbi [Radiochemotherapy of penis carcinoma]
    C Doehn
    Klinik und Poliklinik fur Urologie, Medizinische Universitat, Ratzeburger Allee 160, 23538 Lubeck
    Urologe A 40:313-4. 2001
    ..There is no chemotherapeutic agent of choice to be recommended. The results of radiochemotherapy in patients with T2 tumors or higher are not satisfactory because local tumor control often cannot be achieved...
  23. ncbi Technology evaluation: TG-1031, Transgene SA
    C Doehn
    Department of Urology, Medical University of Luebeck, Ratzeburger Allee 160, 23538 Luebeck, Germany
    Curr Opin Mol Ther 2:106-11. 2000
    ..This therapy has potential for the treatment of breast cancer, prostate cancer and other adenocarcinomas and is currently under investigation in phase I and II trials...
  24. ncbi Laparoscopic fenestration of posttransplant lymphoceles
    C Doehn
    Department of Urology, University of Luebeck Medical School, Ratzeburger Allee 160, 23538 Luebeck, Germany
    Surg Endosc 16:690-5. 2002
    ..g., through transplant dysfunction) this condition has to be treated. We report our 9-year experience with laparoscopic lymphocele fenestration and discuss the current management options for posttransplant lymphoceles...
  25. ncbi Value of acute-phase proteins in the differential diagnosis of acute scrotum
    C Doehn
    Department of Urology, Head Prof Dr D Jocham, Medical University of Lubeck, Germany
    Eur Urol 39:215-21. 2001
    ..However, the differential diagnosis may be difficult in some cases. In a retrospective study, we investigated the value of acutephase proteins in serum and plasma from patients with an acute scrotum...
  26. ncbi Fatal basilar artery thrombosis after chemotherapy for testicular cancer
    C Doehn
    Department of Urology, Medical University of Lubeck, Lubeck, Germany
    Urol Int 65:43-5. 2000
    ..He died 14 h after hospital admission. Cerebrovascular events related to cisplatin-based chemotherapy are rare, however, these potentially fatal events should be kept in mind when treating patients with testicular cancer...
  27. ncbi [Urologic laparoscopy in marginal patients]
    C Doehn
    Klinik und Poliklinik fur Urologie, Medizinische Universitat zu Lubeck, Ratzeburger Allee 160, 23538 Lubeck
    Urologe A 41:123-30. 2002
    ..Although data are scarce concerning other laparoscopic procedures in borderline patients, the results of laparoscopic nephrectomy should probably apply to other laparoscopic procedures...
  28. ncbi Intra-abdominal abscess due to patient non-compliance after construction of an ileal neobladder: case report and review of the literature
    C Doehn
    Department of Urology, Medical University of Lubeck, Germany
    Int J Urol 6:264-7. 1999
    ..A case report of patient with an intra-abdominal abscess 8 weeks after radical cystectomy and construction of an ileal neobladder is presented...
  29. ncbi Renal transplant lithiasis
    C Doehn
    Department of Urology, Medical University of Lubeck, Lubeck, Germany
    Transplant Proc 34:2222-3. 2002
  30. ncbi Technology evaluation: PROSTVAC, Therion
    Christian Doehn
    Department of Urology, University of Lübeck Medial School, Germany
    Curr Opin Mol Ther 4:528-34. 2002
    ..In February 2000, phase II trials had commenced. By October 2001, the drug was undergoing four phase II trials...
  31. ncbi Technology evaluation: MLN-591, Cornell University/BZL Biologics/ImmunoGen/Millennium
    Christian Doehn
    Department of Urology, University of Lubeck Medical School, Ratzeburger Allee 160, 23538 Lubeck, Germany
    Curr Opin Mol Ther 4:606-13. 2002
    ..MLN-591 was in phase II trials by May 2002...
  32. ncbi Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial
    Ch Doehn
    Department of Urology, University of Lubeck Medical School, Lubeck, Germany
    Folia Biol (Praha) 49:69-73. 2003
    ..However, it must be emphasized that the results of the final study report (2003) must be awaited before definite recommendations can be made...
  33. ncbi [Quality of life in urologic oncology: new aspects]
    C Doehn
    Klinik und Poliklinik fur Urologie, Universitätsklinikum Schleswig Holstein Campus Lübeck, Deutschland
    Onkologie 26:30-4. 2003
    ..Beside the development of disease-specific questionnaires, a future major issue is the standardized determination of the parameter quality of life to achieve a basis to compare the results of different studies...
  34. ncbi Technology evaluation: CN-706, Calydon Inc
    C Doehn
    Department of Urology, Medical University of Luebeck, Ratzeburger Allee 160, 23538 Luebeck, Germany
    Curr Opin Mol Ther 2:703-8. 2000
    ..In June 1999, Calydon was issued two further patents [US-05871726], [US-05830686], [327511]...
  35. doi The role of surgery in clinical management of patients with metastatic papillary renal cell carcinoma
    Thomas Steiner
    Department of Urology, University Hospital Jena, Lessingstr 1, 07743 Jena, Germany
    J Cancer Res Clin Oncol 136:905-10. 2010
    ..This study aimed to assess the relevance of surgical and systemic options used in treatment of these patients prior to the recent era of targeted therapies...
  36. ncbi Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial
    Dieter Jocham
    Department of Urology, University of Lubeck Medical School, Ratzeburger Allee 160, 23538 Lubeck, Germany
    Lancet 363:594-9. 2004
    ..At present, no effective adjuvant treatment is established. We aimed to investigate the effect of an autologous renal tumour cell vaccine on risk of tumour progression in patients with stage pT2-3b pN0-3 M0 renal-cell carcinoma...
  37. ncbi In vivo studies on the availability and toxicity of antisense oligonucleotides in bladder cancer
    Caroline E Blietz
    Department of Urology, University of Lubeck, Lubeck, Germany
    In Vivo 23:13-9. 2009
    ..In search of new agents, antisense oligonucleotides (AS-ON) may be interesting candidates. The availability and toxicity as well as the effectivity of AS-ON after intravesical instillation in different rodent models were examined...
  38. ncbi Inhibition of Ki-67 in a renal cell carcinoma severe combined immunodeficiency disease mouse model is associated with induction of apoptosis and tumour growth inhibition
    Ingo Kausch
    Department of Urology, University of Lubeck, Medical School, Ratzeburger Allee 160, 23538 Lubeck, Germany
    BJU Int 95:416-20. 2005
    ....
  39. ncbi Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo
    Andreas Wirger
    Department of Urology, Medical University, 23562 Luebeck, Germany
    Anticancer Res 25:4341-7. 2005
    ..In summary, our results indicated that flavopiridol could be a useful therapeutic agent for bladder cancer, inhibiting tumor growth, malignant progression and inducing apoptosis...
  40. doi Immunotherapy of prostate cancer
    Christian Doehn
    Eur Urol 53:681-3; discussion 684-5. 2008
  41. ncbi Re: a clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma
    Christian Doehn
    J Urol 176:1687. 2006
  42. ncbi Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue
    Wolfram J Jabs
    Department of Medicine I, Division of Nephrology, University of Luebeck School of Medicine, Germany
    Kidney Int 68:2103-10. 2005
    ..Renal tubular epithelial cells are capable of synthesizing CRP. Although production of interleukin (IL)-6 has been described in RCC, CRP expression by carcinoma cells has yet not been investigated...